Microorganisms in the aetiology of atherosclerosis

Journal of Clinical Pathology

Volumn 53, Issue 9, 2000, Pages 647-654

  Morre S A ^a   Stooker, W ^a   Lagrand, W K ^a   Van Den Brule, A J C ^a   Niessen, H W M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Helicobacter pylori

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; COXSACKIE VIRUS B; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HEART INFARCTION; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; MEASLES VIRUS; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROLOGY;

ARTERIOSCLEROSIS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; VIRUS DISEASES;

EID: 0033817345     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.9.647     Document Type: Review

References (117)

1. 1 Capron L, Wyplosz B. The infection theory in atherosclerosis. Arch Mal Cocur Vaiss 1998;91:21-6.
2. 2 Libby P, Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs 1998;56:9-13.
3. 3 Jander S, Sitzer M, Schumann R, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke 1998;29:1625-30.
4. 4 Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-5.
5. 5 Muhlestein JB. Bacterial infections and atherosclerosis. J Investig Med 1998;46:396-402.
6. 6 Beck JD, Slade GD. Epidemiology of peridontal diseases. Current Opinion Peridontology 1996;3:3-9.
7. 7 Matilla KJ, Valle MS, Nieminen MS, et al. Dental infections and coronary atherosclerosis. Atherosclerosis 1993;103:205-11.
8. 8 Matilla KJ. Dental infections as a risk factor for acute myocardial infarction. Eur Heart J 1993;14:51-3.
9. 9 Adams MR, Nakagomi A, Keech A, et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 1995;92:2127-34.
10. 10 Meier CR, Derby LE, Jick SS, et al. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999;281:427-31.
11. 11 Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998;66: 5067-72.
12. 12 Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998;177:725-9.
13. 13 Godzik KL, O'Brien ER, Wang SK, et al. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995;33:2411-14.
14. 14 Halme S, Syrjala H, Bloigu A., et al. Lymphocyte responses to chlamydia antigens in patients with coronary heart disease. Eur Heart J 1997;18:1095-101.
15. 15 Molestina RE, Dean D, Miller RD, et al. Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells. Infect Immun 1998;66: 1370-6.
16. 16 Kol A, Sukhova GK, Lichtman AH, et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998;98: 300-7.
17. 17 Tiran A, Tio RA, Ossewaarde JM, et al. Coronary angioplasty induces a rise in Chlamydia pneumoniae-specific antibodies. J Clin Microbiol 1999;37:1013-17.
18. 18 Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherchia coli and Chlamydia pneumoniae. Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999;99:1560-6.
19. 19 Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
20. 20 Laitinen K, Laurila A, Pyhala I., et al. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997;65:4832-5.
21. 21 Moazed TC, Kuo C, Grayston JT, et al. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997;175:883-90.
22. 22 Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103;747-53.
23. 23 Kuo C, Campbell LA. Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis? Mol Med Today 1998;4:426-30.
24. 24 Fagerberg B, Gnarpe J, Gnarpe H, et al. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease. A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999;30:299-305.
25. 25 Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis risk in communities (ARIC) study investigators. Am J Med 1993;95:499-504.
26. 26 Ossewaarde JM, Feskens EJ, De Vries A, et al. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998;120:93-9.
27. 27 Laurila A, Bloigu A, Nayha S, et al. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2910-13.
28. 28 Boman J, Soderberg S, Folsberg J, et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998;178:274-7.
29. 29 Wong YK, Dawkins K, Ward ME. Detection of C. pneumoniae DNA circulating in the blood of patients attending for cardiac angiography: preliminary clinical and serological correlates. In: Stephens RS, Byrne GI, Christiansen G, et al, eds. Chiamydial infections. Proceedings of the ninth international symposium on human chlamydial infection. International Chlamydial Symposium, San Francisco. 1998: 227-30.
30. 30 Sinisalo J, Matilla K, Nieminen MS, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998;41:85-92.
31. 31 Ridker PM, Kundsin RB, Stampfer MJ, et al. Prospective study of Chlamydia pneumoniae IgG seropositivity and risk of future myocardial infarction. Circulation 1999:99: 1161-4.
32. 32 Altman R, Rouvier J, Scazziota A, et al. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cardiol 1999; 22:85-90.
33. 33 Yamashita K, Ouchi K, Shirai M, et al. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 1998;29:773-8.
34. 34 Jackson LA, Campbell LA, Kuo CC, et al. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176:292-5.
35. 35 Maass M, Krause E, Engel PM, et al. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology 1997;48: 699-706.
36. 36 Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery, Circulation 1995;92:3397-400.
37. 37 Davidson M, Kuo CC, Middaugh JP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-33.
38. 38 Blasi F, Denti F, Erba M, et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996;34: 2766-9.
39. 39 Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27: 1555-61.
40. 40 Kuo CC, Coulson AS, Campbell LA, et al. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 1997;26:29-31.
41. 41 Kuo CC, Grayston JT, Campbell LA, et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A 1995;92:6911-14.
42. 42 Kuo CC, Gown AM, Benditt EP, et al. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993; 13:1501-4.
43. 43 Bartels C, Maass M, Bein G, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999;99: 879-82.
44. 44 Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998;31: 827-32
45. 45 Juvonen JJ, Tuvonen T, Laurila A, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997;25:499-505.
46. 46 Ramirez JA, Ahkee S, Summersgill JT, et al. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996;125:979-82.
47. 47 Shor A, Phillips JL, Ong G, et al. Chlamydia pneumoniae in atheroma - consideration of criteria for causality. J Clin Pathol 1998;51:812-17.
48. 48 Nystromrosander C, Thelin S, Hjelm E, et al. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Scand J Infect Dis 1997;29:361-5.
49. 49 Paget CJ, Wolk SW, Whitehouse WM, et al. Incidence and pathophysiologic significance of infected carotid artery plaque. Ann Vasc Surg 1997;11:129-32.
50. 50 Paterson DL, Hall J, Rasmussen SJ, et al. Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology 1998;30:169-72.
51. 51 Lindholt JS, Osterdard L, Henneberg EW, et al. Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR). Eur J Vasc Endovasc Surg 1998;15:161-4.
52. 52 Andreasen JJ, Farholt S, Jensen JS. Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery. APMIS 1998;106:717-20.
53. 53 Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumonia antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
54. 54 Gurfinkel E, Bozovich G, Daroca A, et al. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
55. 55 Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999;20:121-7.
56. 56 Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumonia infection. Circulation 1999;99: 1540-7.
57. 57 Gibbs RG, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg 1998;85:1191-7.
58. 58 Stille W, Dittmann R. Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection. Herz 1998;23: 185-92.
59. 59 Maass M. Persistence of Chlamydia pneumoniae in human arteriosclerotic plaque substance. Evidence and consequences. Herz 1998;23:187-4.
60. 60 Das UN. Hypothesis: cis-unsaturated fatty acids as potential anti-peptic ulcer drugs. Prostaglandins Leukot Essent Fatty Acids 1998;58:377-80.
61. 61 Laurila A, Bloigu A, Nayha S, et al. Association of helicobacter infection with elevated serum lipids. Atherosclerosis 1999;142:207-10.
62. 62 Markus HS, Mendall MA. Helicobacter pylori infection: a risk factor for ischaemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry 1998;64: 104-7.
63. 63 Birnie DH, Holme ER, McKay IC, et al. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action to Helicobacrer pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998;19:387-94.
64. 64 Ossei-Gerning N, Moayyedi P, Smith S, et al. Helicobacter pylori infection is related to atheroma in patients undergoing coronary angiography. Cardiovasc Res 1997;35:120-4.
65. 65 Folsom AR, Nieto FJ, Sorlie P, et al. Helicobacter pylori scropositivity and coronary heart disease incidence. Atherosclerosis risk in communities (ARIC) study investigators. Circulation 1998;98:845-50.
66. 66 Regnstrom J, Jovinge S, Bavenholm P, et al. Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J Intern Med 1998;243:109-13.
67. 67 Pesonen E, Paakkari I, Rapola J. Infection-associated intimal thickening in the coronary arteries of children. Atherosclerosis 1999;142:425-9.
68. 68 Constans J, Marchand JM, Conri C, et al. Asymptomatic atherosclerosis in HIV-patients: a case control ultrasound study. Am Med 1995;27:683-5.
69. 69 Paton P, Tabib A, Loire R, et al. Coronary lesions and immunodeficiency virus infection. Res Virol 1993;144:225-31.
70. 70 Iiback NG, Mohammed A, Fohlman J, et al. Cardiovascular lipid accumulation with Coxsacki B virus infection in mice. Am J Pathol 1990;136:159-67.
71. 71 Roivainen M, Alfthan G, Jousilahti P, et al. Enterovirus infections as a possible risk factor for myocardial infarction. Circulation 1998;98:2534-7.
72. 72 Nicholls AC, Thomas M. Coxsacki virus infection in acute myocardial infarction. Lancet 1977;1:883-4.
73. 73 Griffiths PD, Hannington G, Booth JC. Coxsacki B virus infection and myocardial infarction. Lancet 1980;1;1387-9.
74. 74 Vercellotti GM. Effects of viral activation of the vessel wall on inflammation and thrombosis. Blood Coagul Fibrinolysis 1998;9:S3-6.
75. 75 Speir E, Yu ZX, Ferrans VJ, et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 1998;83:210-16.
76. 76 Span AH, Van Boven CP, Bruggeman CA. The effect of cytomegalovirus infection on the adherence of polymorphonuclear leucocytes to endothelial cells. Eur J Clin Invest 1989;19:542-8.
77. 77 Guetta E, Guetta V, Shibutani T, et al. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Circ Res 1997;81:8-16.
78. 78 Yonemitsu Y, Kaneda Y, Komori K, et al. The immediate early gene of human cytomegalovirus stimulates vascular smooth muscle cell proliferation in vitro and in vivo. Biochem Biophys Res Commun 1997;231:447-51.
79. 79 Melnick JL, Petrie BL, Dreesman GR, et al. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983;2:644-7.
80. 80 Berencsi K, Endresz V, Klurfeld D, et al. Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice. Cell Adhes Commun 1998;5:39-47.
81. 81 Persoons MC, Daemen MJ, Bruning JH, et al. Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats. A clue to herpesvirus-associated atherogenesis? Circ Res 1994;75:214-20.
82. 82 Sorlie PD, Adam E, Melnick SL, et al. Cytomegalovirus/ herpesvirus and carotid atherosclerosis: the ARIC study. J Med Virol 1994;42:33-7.
83. 83 Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996;94:922-7.
84. 84 Herzum M, Schaefer JR, Hufnagel G, et al. Cytomegalovirus and herpes simplex virus in pathogenesis and progression of native arteriosclerosis and recurrent stenosis after intervention. Herz 1998;23:193-6.
85. 85 Blum A, Giladi M, Weinberg M, et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998;81:866-8.
86. 86 Adam E, Melnick JL, Probtsfield JL, et al. High levels, of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987;2:291-3.
87. 87 Visseren FI, Bouter KP, Pon MJ, et al. Patients with diabetes mellitus and atherosclerosis; a role for cytomegalovirus? Diabetes Res Clin Pract 1997;36:49-55.
88. 88 Musiani M, Zerbini ML, Muscari A, et al. Antibody patterns against cytomegalovirus and Epstein-Barr virus in human atherosclerosis. Microbiologica 1990; 13:35-41.
89. 89 Adler SP, Hur JK, Wang JB, et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998;177:209-12.
90. 90 Tiran A, Tio RA, Oostenveld E, et al. Humoral immune response to human cytomegalovirus in patients undergoing percutaneous transluminal coronary angioplasty. Clin Diagn Lab Immunol 1999;6:45-9.
91. 91 Hendrix MG, Salimans MM, van Boven CP, et al. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136:23-8.
92. 92 Hendrix MG, Dormans PH, Kitslaar P, et al. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclcrotic patients. Am J Pathol 1989;134:1151-7.
93. 93 Yonemitsu Y, Komori K, Sueishi K, et al. Possible role of cytomegalovirus infection in the pathogenesis of human vascular diseases. Nippon Rinsho 1998;56:102-8.
94. 94 Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993;14:30-8.
95. 95 Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261: 3561-6.
96. 96 Loebe M, Schuler S, Spiegelsberger S, et al. Cytomegalovirus infection and coronary sclerosis after heart transplantation. Deutsche Med Wochenschr 1990;115:1266-9.
97. 97 Fang JC, Kinlay S, Kundsin R, et al. Chlamydia pneumoniae infection is frequent but not associated with coronary atherosclerosis in cardiac transplant recipients. Am J Cardiol 1998;82:1479-83.
98. 98 Adam E, Melnick JL, DeBakey ME. Cytomegalovirus infection and atherosclerosis. Cent Eur J Public Health 1997;5:99-106.
99. 99 Musiani M, Zerbini ML, Muscari A, et al. Antibody patterns against cytomegalovirus and Epstein-Barr virus in human atherosclerosis. Microbiologica 1990;13:35-41.
100. 100 Yamashiroya HM, Ghosh L, Yang R, et al. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988;130:71-9.
101. 101 Straka F, Malek I, Stanek V, et al. Coronary disease in patients after heart transplantation. Cor Vasa 1993;35: 267-75.
102. 102 Key NS, Vercellotti GM, Winkelmann JC, et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A 1990;87: 7095-9.
103. 103 Kaner RJ, Medina J, Nicholson AC, et al. Developmentally regulated herpesvirus plaque formation in arterial smooth muscle cells. Circ Res 1993;73:10-14.
104. 104 Hajjar DP, Pomerantz KB, Falcone DJ, et al. Herpes simplex virus infection in human arterial cells. Implications in arteriosclerosis. J Clin Invest 1987;80:1317-21.
105. 105 Visser MR, Vercellotti GM. Herpes simplex virus and atherosclerosis. Eur Heart J 1993;14:39-42.
106. 106 Key NS, Bach RR, Vercellotti GM, et al. Herpes simplex virus type I does not require productive infection to induce tissue factor in human umbilical vein endothelial cells. Lab Invest 1993;68:645-51.
107. 107 Span AH, van Dam-Mieras MC, Mullers W, et al. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells. Eur J Clin Invest 1991;21: 331-8.
108. 108 Visser MR, Jacob HS, Goodman JL, et al. Granulocyte-mediated injury to herpes simplex virus-infected human endothelium. Lab Invest 1989;60:296-304.
109. 109 Mattila KJ, Valtonen VV, Nieminen MS, et al. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998;26:719-34.
110. 110 Raza-Ahmad A, Klassen GA, Murphy DA, et al. Evidence of type 2 herpes simplex infection in human coronary arteries at the time of coronary artery bypass surgery. Can J Cardiol 1995;11:1025-9.
111. 111 Bayad J, Galteau MM, Siest G. Viral theory of atherosclerosis. Role of cytomegalovirus. Ann Biol Clin (Paris) 1993; 51:101-7.
112. 112 Jacob HS, Visser M, Key NS, et al. Herpes virus infection of endothelium: new insights into atherosclerosis. Trans Am Clin Climatol Assoc 1992;103:95-104.
113. 113 Csonka E, Bayer PI, Buki K, et al. Influence of the measles virus on the proliferation and protein synthesis of aortic endothelial and smooth muscle cells. Acta Microbiologica Hungarica 1990;37:193-200.
114. 114 Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
115. 115 Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-92.
116. 116 Bachmeier K, Neu N, de la Maza LM, et al. Chlamydia infection and heart disease linked through antigenic mimicry. Science 1999;283:1335-9.
117. 117 Nicoletti A, Kaveri S, Caligiuri G, et al. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998;102:910-18.